Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8107665 | 0.88 | CYP1A2 (0.58) | AAK1CYP1A2CYP2C19NPSR1MAPT | |
| SCHEMBL30334729 | 0.85 | CYP1A2 (0.63) | AAK1CYP1A2CYP2C19NPSR1MAPT | |
| SCHEMBL5582783 | 0.85 | CYP1A2 (0.63) | AAK1CYP1A2CYP2C19NPSR1MAPT | |
| SCHEMBL4224574 | 0.80 | MAPK14 (0.65) | AAK1CYP1A2MAPTMAOANPC1 | |
| SCHEMBL11110158 | 0.76 | MAPT (0.46) | AAK1CYP1A2CYP2C19NPSR1MAPT | |
| SCHEMBL7820586 | 0.76 | AAK1 (0.55) | AAK1CYP1A2CYP2C19NPSR1MAPT | |
| SCHEMBL15972747 | 0.76 | AAK1 (1.00) | AAK1ROCK2 | |
| SCHEMBL10361399 | 0.76 | MAOB (0.62) | MAPTMAOANPC1RAB9AHSD17B10 | |
| SCHEMBL5764438 | 0.75 | MAPT (0.68) | CYP1A2NPSR1MAPTBAZ2BMAOA | |
| SCHEMBL2314738 | 0.74 | AAK1 (0.52) | AAK1MAPTNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658647-A1 | TRICYCLIC AZEPINONE DERIVATIVES AS SYSTEM XC INHIBITORS | UCB Biopharma SRL (BE) | 2025-12-10 | — | — | EP | claimed |
| WO-2024160722-A1 | TRICYCLIC AZEPINONE DERIVATIVES AS SYSTEM XC INHIBITORS | UCB Biopharma SRL (BE) | 2024-08-08 | — | — | WO | claimed |
| EP-4658647-A1 | TRICYCLIC AZEPINONE DERIVATIVES AS SYSTEM XC INHIBITORS | UCB Biopharma SRL (BE) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024160722-A1 | TRICYCLIC AZEPINONE DERIVATIVES AS SYSTEM XC INHIBITORS | UCB Biopharma SRL (BE) | 2024-08-08 | — | — | WO | disclosed |
| US-20230295103-A1 | AURONE DERIVATIVES AND USES THEREOF FOR CONTROLLING BACTERIA AND/OR FUNGI | ECOLE CENTRALE DE MARSEILLE (FR) | 2023-09-21 | — | — | US | disclosed |
| US-20230295103-A1 | AURONE DERIVATIVES AND USES THEREOF FOR CONTROLLING BACTERIA AND/OR FUNGI | ECOLE CENTRALE DE MARSEILLE (FR) | 2023-09-21 | — | — | US | disclosed |
| WO-2022008678-A2 | AURONE DERIVATIVES AND USES THEREOF FOR CONTROLLING BACTERIA AND/OR FUNGI | UNIVERSITE D'AIX-MARSEILLE (FR) | 2022-01-13 | — | — | WO | disclosed |
| EP-1751127-B1 | NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | INTERMED DISCOVERY GMBH (DE) | 2012-07-11 | — | — | EP | disclosed |
| EP-1751127-B1 | NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | INTERMED DISCOVERY GMBH (DE) | 2012-07-11 | — | — | EP | disclosed |
| US-8030347-B2 | Cylopenta[b]benzofuran derivatives and the utilization thereof | BAYER HEALTHCARE AG (DE) | 2011-10-04 | — | — | US | disclosed |
| US-8030347-B2 | Cylopenta[b]benzofuran derivatives and the utilization thereof | BAYER HEALTHCARE AG (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20090018113-A1 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof | BAYER HEALTHCARE AG (DE) | 2009-01-15 | — | — | US | disclosed |
| EP-1751127-A2 | NOVEL CYLOPENTA¬B|BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | Bayer HealthCare AG (DE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005113529-A2 | NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | BAYER HEALTHCARE AG (DE) | 2005-12-01 | — | — | WO | disclosed |
| EP-0685475-B1 | Amino-benzofuryl-and thienyl-derivatives | BAYER AG (DE) | 1999-01-13 | — | — | EP | disclosed |
| EP-0685474-B1 | Oxalylamino-benzofuran- and benzothienyl-derivatives | BAYER AG (DE) | 1998-09-16 | — | — | EP | disclosed |
| US-5622989-A | ANTIINFLAMMATORY AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-04-22 | — | — | US | disclosed |
| US-5565488-A | ANTIINFLAMMATORY AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-10-15 | — | — | US | disclosed |
| EP-0685475-A1 | Amino-benzofuryl-and thienyl-derivatives | BAYER AG (DE) | 1995-12-06 | — | — | EP | disclosed |
| EP-0685474-A1 | Oxalylamino-benzofuran- and benzothienyl-derivatives | BAYER AG (DE) | 1995-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295103-A1 | AURONE DERIVATIVES AND USES THEREOF FOR CONTROLLING BACTERIA AND/OR FUNGI | AURKA, CYP51A1, AURKC | AAK1 698/4885CYP1A2 113/4885CYP2C19 576/4885 |
| US-20090018113-A1 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof | FKBP1A, FKBP2, FKBP1B | AAK1 3083/4885CYP1A2 1651/4885CYP2C19 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.